2414254-52-5
Chemical Structure
(1S)-Rezetecan
Synonym(s): (1S)-SHR9265; MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan
- CAS No.: 2414254-52-5
- Formula:C55H60FN9O13
- Molecular Weight:1074.12
IUPAC Name: (1s,3s)-3-(2-(4-(8-chloro-4-oxo-4H-chromen-2-yl)phenoxy)ethoxy)cyclobutane-1-carboxylic acid
InChIKey: WKCCHLIWLNJSMH-DVXRIDOZSA-N
SMILES: O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCO[C@@H](C3CC3)C(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O)=O
Biological Activity: (1S)-Rezetecan ((1S)-SHR9265; MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan) is an isomer of Rezetecan (HY-148668). Rezetecan is a topoisomerase I inhibitor with cytotoxicity. Rezetecan can serve as an antibody-drug conjugate payload (ADC Payloads), for example, it participates in the synthesis of Tizetatug rezetecan (HY-177711). Rezetecan is applicable to research related to various cancers such as breast cancer and gastric cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(1S)-Rezetecan | 98.99% | (1S)-Rezetecan ((1S)-SHR9265; MC-Gly-Gly-Phe-Gly-(S)-Cyclopropane-Exatecan) is an isomer of Rezetecan (HY-148668). Rezetecan is a topoisomerase I inhibitor with cytotoxicity. Rezetecan can serve as an antibody-drug conjugate payload (ADC Payloads), for example, it participates in the synthesis of Tizetatug rezetecan (HY-177711). Rezetecan is applicable to research related to various cancers such as breast cancer and gastric cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang T, et al. Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles. Cancer Research, 2023, 83(8_Supplement): LB031.
- [2]. Wang B, et al. Preclinical activity of SHR-A1921, a novel antibody-drug conjugate targeting trophoblast cell-surface antigen2 (Trop-2) in prostate cancer. Frontiers in pharmacology. 2026;17:1713983. [Content Brief]
